Yasir Haider Al-Mawlah is an accomplished oncology- and biotechnology-oriented researcher and academic based at the DNA Research Center, University of Babylon, Iraq, with a strong interdisciplinary background spanning molecular biology, biotechnology, forensic genetics, and cancer-related research. He holds a verified academic appointment at the University of Babylon and has established a solid scientific profile with more than 220 citations, an h-index of 9, and an i10-index of 8, reflecting consistent scholarly impact over several years. His oncology-related work focuses primarily on molecular mechanisms of cancer development, genetic susceptibility, and biomarker discovery, particularly in breast cancer. He has contributed significantly to studies examining genetic polymorphisms in antioxidant enzymes such as SOD, CAT, and GPx1 and their association with breast cancer risk, oxidative stress, and biomarker alterations, providing insights into cancer pathogenesis and potential diagnostic indicators. In addition, his research includes anti-cancer evaluations of natural compounds, such as plant-derived alkaloids, against human breast cancer cell lines, highlighting translational approaches that bridge natural product research and oncology therapeutics. Beyond cancer, his scientific contributions extend to microRNA expression profiling, including fertility, forensic identification, and body fluid differentiation, demonstrating advanced expertise in non-coding RNA stability and specificity. He has also published widely on antimicrobial nanoparticles, nanobiotechnology, and multidrug-resistant pathogens, reflecting a broader biomedical scope relevant to cancer-associated infections and clinical complications. Dr. Al-Mawlah collaborates extensively with multidisciplinary teams across medical microbiology, genetics, pharmacology, and clinical sciences, both within Iraq and internationally. His publication record in peer-reviewed journals, combined with sustained citation performance, underscores his role as an active contributor to contemporary biomedical and oncology-related research, with work that supports early diagnosis, molecular risk assessment, and innovative therapeutic exploration in cancer and related diseases.
Profile: Google Scholar
Featured Publications
Al-Mawlah, Y. H., Al-Darraji, M. N., & Al-Imari, M. J. (2022). Study of small non-coding RNA (miRNA) expression pattern of fertile/infertile male semen. Acta Informatica Medica, 30(3), 205–210.
Abdulazeem, L., Al-Alaq, F. T., Alrubaei, H. A., Al-Mawlah, Y. H., & Alwan, W. K. (2018). Anti-cancer activity of Opuntia polyacantha alkaloid extract on human breast cancer cell line. Journal of Pharmaceutical Sciences and Research, 10(7), 1753–1754.
Al-Mawlah, Y. H., Alasadi, Y. F., & Al-Darraji, M. N. (2021). Association between genetic polymorphisms of Cu/ZnSOD and CAT C262T and the risk of breast cancer. Gene Reports, 25, 101401.
Abdulazeem, L., Al-Amiedi, B. H., Alrubaei, H. A., & Al-Mawlah, Y. H. (2019). Titanium dioxide nanoparticles as antibacterial agents against some pathogenic bacteria. Drug Invention Today, 12(5), 963–967.
Al-Mawlah, Y. H., Naji, M. Z., Al-Imari, M. J., & Abdulabbas, H. S. (2022). Micro-RNA evaluation, specification, and stabilization study in mixed and non-mixed body fluids as a specific molecular marker. Journal of Advanced Biotechnology and Experimental Therapeutics, 5(2), 347–357.
Through integrative research in oncology, molecular genetics, and biotechnology, the nominee advances scientific understanding of cancer risk, biomarker discovery, and molecular diagnostics. His work bridges fundamental research with applied innovation, supporting early detection, personalized medicine, and translational solutions that benefit public health and biomedical development.